Table 1.
Opioid use disorder (OUD) treatment practices among U.S. primary care physician survey respondents (N=336)
| Provision of OUD treatment | Percent of respondents (95% CI) |
|---|---|
| Percent of primary care physicians who report that they: | |
| Prescribe either buprenorphine or injectable extended-release naltrexone for OUD | 9.4 (6.7, 13.0) |
| Prescribe buprenorphine (also called Suboxone or Subutex) for OUD | 7.1 (4.8, 10.4) |
| Prescribe injectable extended-release naltrexone (also called Vivitrol) for OUD | 4.4 (2.7, 7.2) |
| Provide OUD counseling themselves | 35.3 (30.3, 40.7) |
| Referral to OUD treatment1 | |
| Percent of primary care physicians who report that they: | |
| Refer patients to another clinician who prescribes buprenorphine, injectable extended-release naltrexone, or methadone for OUD | 52.4 (46.7, 58.1) |
| Refer patients to another clinician who prescribes buprenorphine for OUD | 46.3 (40.7, 52.0) |
| Refer patients to another clinician who prescribes injectable extended-release naltrexone for OUD | 22.4 (18.0, 27.5) |
| Refer patients to an OUD methadone treatment program | 17.9 (13.9, 22.7) |
| Refer patients to OUD counseling | 79.7 (73.6, 84.6) |
| Refer patients to OUD counseling outside their practice | 67.6 (60.9, 73.6) |
| Refer patients to OUd counseling inside their practice | 20.8 (15.9, 26.8) |
1
Among primary care physician respondents who do not provide treatment themselves.